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C9orf72 hexanucleotide repeat length in older population: normal variation and effects on cognition Karri 
Introduction
C9orf72 hexanucleotide repeat expansion is a major cause of sporadic and familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (DeJesus-Hernandez et al., 2011 , Renton et al., 2011 ) and it's particularly common in Finland (Majounie et al., 2012) . Expansions can span up to several thousand repeats, but the minimum length of pathogenic expansion is not known. Knowledge on the distribution of repeat lengths in the general population could help gain a better understanding of the threshold for pathogenicity. Perhaps the most widely used threshold for expansion is 30, defined in one of the original studies describing the C9orf72 repeat (Renton et al., 2011) . Determining a threshold for expansion is complicated by the difficulty of reliably determining repeat lengths, and thresholds reflect more the limitation of used methods than actual alteration in biologic function.
Southern blot is considered to be the golden standard of repeat length estimation but due to its high M A N U S C R I P T
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demand of good quality DNA, cost and work load, often other methods such as repeat-primed PCR (RP-PCR) are used.
Besides genuine expansions, "intermediate length" alleles (defined often as 7-30 or 20-30 repeats) have also been hypothesized to predispose to neurodegenerative diseases. In luciferase reporter assay, intermediate alleles showed decreased C9orf72 promoter activity as compared to short repeat alleles (Gijselinck et al., 2016) . Moreover, adverse effects have been observed in a fly model with 30 repeats though the relevance of fly physiology to human pathophysiology in this context is unsure. As with expansion, the threshold for intermediate length repeats also varies in studies but allele length ≥7 has been shown to associate with the C9orf72 founder haplotype in the European population (van der Zee et al., 2013a) . A recent review (Ng and Tan, 2017) (Cacace et al., 2013a , Harms et al., 2013 , Jiao et al., 2013 , Kohli et al., 2013a , Xi et al., 2012 .
In this study, we present C9orf72 hexanucleotide repeat length distribution in 3142 Finns and study the association of intermediate repeat alleles with AD and cognitive impairment.
Methods

Cohorts
We studied the C9orf72 hexanucleotide repeat length in 3161 individuals from four populationderived cohorts from the Helsinki-region, in Southern Finland. These were the Vantaa85+ study (Tanskanen et al., 2017 ) (n=469), Helsinki Birth cohort study (Barker et al., 2005 , Eriksson et al., 2006 , Kajantie et al., 2012 , Lahti et al., 2014 , Yliharsila et al., 2007 ) (n=1651), Helsinki Businessmen study (Strandberg et al., 2016) (n=666) and DEBATE study (Uusvaara et al., 2013) (n=375) . We have previously used the same cohorts to study the association of TYROPB deletion and cognitive impairment (Kaivola et al., 2018) . Information on AD, other dementia diagnoses, Mini Mental State Examination (MMSE) scores or lack of dementia was assessed from clinical records, death certificates, 
Genetic analyses
We determined repeat lengths with RP-PCR as previously described (Renton et al., 2011) were no samples homozygous for the 20-45 repeat alleles in our cohorts. APOE was genotyped as previously described (Myllykangas et al., 1999) .
Statistics
We used logistic regression to test for association between intermediate repeats in all three settings and used APOE ε4 carriership, age and sex as covariates. We applied Bonferroni correction to take account of multiple test settings and set the statistical significance to p=0.05/3=0.017. We used Kruskal-Wallis H test to determine if repeat length distributions differed between our four cohorts. All 
Ethics
The study was approved by the Coordinating Ethics Committee of the Helsinki University Central
Hospital. The Vantaa 85+ study was also approved by the Ethics Committee of the Health Centre of the City of Vantaa.
Results
Repeat length distribution
We successfully determined repeat lengths in 3142/3161 (99.3 %) individuals. There was no statistically significant difference in the repeat length distributions between cohorts (H(3)=2.129, p=0.55). Repeat length distribution of all alleles is shown in Figure 1 Interestingly, repeat lengths ≥20 were more common in Finland than reported elsewhere in previous large studies. To compare the frequency of ≥20 repeat lengths, we searched PUBMED for large population based (>1000 individuals) and case-control studies (>1000 controls) with C9orf72 repeat length distribution available. Besides the original articles describing the repeat, we identified nine M A N U S C R I P T
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articles (Beck et al., 2013 , Cacace et al., 2013b , Fahey et al., 2014 , He et al., 2015 , Kohli et al., 2013b , Nuytemans et al., 2013 , Rutherford et al., 2012 , Theuns et al., 2014 , van der Zee et al., 2013b but only four had enough detailed information on ≥20 repeats for comparison. In these four studies, the prevalence of ≥20 repeats was significantly lower than in Finland (all allelic frequencies <0.56 % and all p<0.019, Fisher's exact test) ( Table 1) . Of the nine studies, only two found expansion carriers in their control groups with carrier frequency of 1/5748 (p=0.0095 vs. our Finnish sample, Fisher's exact test) (Theuns et al., 2014) and 11/7579 (p=0.60 vs. FIN) (Beck et al., 2013) .
Intermediate repeat length alleles, Alzheimer's disease and cognitive impairment
Number of individuals in each cohort with or without Alzheimer's disease/cognitive impairment is shown in Supplementary Table 1.
Alzheimer's disease
We identified 226 individuals with AD (68-97 years, mean age 86, 58% female, 33 % carried 7-45 repeats, 1.3% carried 20-45 repeats) and 893 controls (aged 75-101, mean age 83, 58% female, 33% , OR 2.69, CI 1.97 -3.68) were statistically significantly associated with AD but sex was not (p=0.45).
MMSE scores
When individuals were divided based only on MMSE score into cases (MMSE score ≤24, n=432, aged 61-99, mean age 85, 75% female, 27% carried 7-45 repeats, 1.6% carried 20-45 repeats) and controls (MMSE score ≥25, n=719, aged 75-98, mean age 80, 38% female, 33% carried 7-45 repeats, 1.3% , OR 1.8, CI 1.4 -2.2) associated significantly with dementia or cognitive impairment.
Neurodegenerative and psychiatric diagnoses
We did not find any evident clustering of neurodegenerative or psychiatric disease in the 12 (0.38%) individuals with 30-45 repeats (Table 2 ). There were six (0.19%) expansion carriers and none had diagnosis of ALS or FTD; two had died at ages of 60 and 68 years due to coronary artery disease. Of Table 2 .
Discussion:
The C9orf72 hexanucleotide repeat expansion is a major cause of ALS/FTD, however, what repeat lengths are pathogenic is still unclear. Our data on 3142 older individuals shows that 30-45 repeats are found in 0.38% (1 per 262) individuals and they did not have any apparent clustering of neurodegenerative or psychiatric disease. Our data suggest that 30-45 repeat alleles should not be M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
considered unequivocally pathogenic and other risk factors than the C9orf72 expansion should be considered in patients with these alleles. The smallest expansions that segregate with combinations of ALS, FTD-ALS and "FTLD or dementia" are reportedly ca. 55-100 repeats as measured by Southern blot (Gijselinck et al., 2016) . However, an individual with 70 repeats without neurodegeneration at the age of 90 has been reported (McGoldrick et al., 2018) . More data is still needed for more precise estimation of the pathological threshold, which may actually turn out as a "grey zone" where disease penetrance is dependent on modulating cofactors.
Our data is in line with previous studies indicating a lack of major association between intermediate repeats and AD. Somewhat surprisingly, there was a nominally significant association between 7-45 repeat length alleles and better cognition. This association was not statistically significant in any of the individual cohorts and was only seen in the pooled dataset. This can be a spurious association, but nevertheless, it supports the hypothesis that ≥7 repeat alleles do not predispose to cognitive impairment or dementia. Across all our cohorts, there was heterogeneity in sex and age distributions, variation in socioeconomic status and educational history (one cohort consisted solely of men with high socioeconomic status) and there was no uniform way of defining cognition and dementia status and this information was collected from several sources. Despite these limitations, we found a clear association between APOE ε4 genotype and AD (p=5.5 x 10 -10 , OR 2.69), cognitive impairment (p=0.00078, OR 1.7) and overall dementia status (p=4.0x10 -7 , OR 1.8) which argues against a major bias in our definition of dementia. Furthermore, the Finnish national registers have been found to identify dementia cases accurately (Solomon et al., 2014) .
None of the six expansion carriers we identified had a diagnosis of ALS or FTD but four had a diagnosis of a neurodegenerative or psychiatric disease. Two had died of coronary heart disease before the age of 70 and others were under 80 years. Therefore, it's possible that some expansion carriers could have developed or may develop ALS/FTD in their later years.
Previous reports have shown that C9orf72 expansion is especially common cause of ALS/FTD in Finland (Majounie et al., 2012) . In the present study, the expansion frequency in older Finns (median age 77) was only slightly higher than in the UK 1958 birth cohort. However, this UK population was considerably younger (age ca. 54-55 years during publication in 2013) than our Finnish sample. The M A N U S C R I P T
penetrance of the C9orf72 expansion is known to be strongly age-related; nearly complete penetrance was observed by 83 years in a cohort of 1,147 ALS and FTD cases. The median age of onset varied somewhat with phenotype but was estimated to be around 58 years (Murphy et al., 2017) . Therefore, it can be expected that the expansion frequency in the UK cohort will markedly decrease by time. In line with age-related penetrance, the expansions were unequally distributed in our cohorts; all Finnish expansion carriers were from the HBCS cohort, whose participants were the youngest of the four cohorts (born 1934-1944 , and registry information available up till December 31 of 2013, Supplementary methods). If we restrict the analysis to this cohort only, expansion prevalence would be 6/1644 (0.36% or 1 in 274) in Finland.
Interestingly, we found that non-expanded repeat lengths ≥20 are roughly twice as common in Finland than in other reported populations (Table 1 ). This finding may have a connection with the high frequency of C9orf72 expansion in Finland and raises the question, whether the ≥20 repeat alleles could be prone to germline instability and expansion in the offspring. In this scenario, the larger intermediate alleles would form a pool from which new expansions can be derived, a mechanism shown in families with sporadic Huntington's disease and in Huntington's disease CAG repeat knock-in mice (Goldberg et al., 1993 , Myers et al., 1993 , Wheeler et al., 1999 . Somatic instability (mosaicism) of the expansion has been previously demonstrated (Dols-Icardo et al., 2014 , Fratta et al., 2015 and at least one family has been described, in which an unaffected 90-year-old father had a 70-repeat allele in blood (premutation), which was transmitted to four offspring who all had expansion in blood DNA (McGoldrick et al., 2018) . Whether the expansion was present in the father's sperm could not be tested. However, mosaicism with large expansions was demonstrated in other tissues, therefore it is likely that the expansion was present in sperm. As more than half of the Finnish ALS patients with the C9orf72 expansion are sporadic (Majounie et al., 2012) (Laaksovirta et al unpublished data) the spectrum of premutations warrants further research by genotyping sporadic C9orf72 ALS cases' parents when possible. Another approach would be to genotype paired DNA samples from blood and gametes (Martorell et al., 2004) , especially in carriers of the longer alleles. References are provided in the manuscript. 
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